{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:22:53Z","timestamp":1793164973935,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00277-023-05301-7","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T07:01:41Z","timestamp":1686207701000},"page":"2153-2163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study"],"prefix":"10.1007","volume":"102","author":[{"given":"Junnan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"issue":"Suppl 5","key":"5301_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","volume":"14","author":"TA Dolecek","year":"2012","unstructured":"Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005\u20132009. Neuro Oncol 14(Suppl 5):v1-49","journal-title":"Neuro Oncol"},{"issue":"21","key":"5301_CR2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS Lymphoma. J Clin Oncol 35(21):2410\u20132418","journal-title":"J Clin Oncol"},{"key":"5301_CR3","doi-asserted-by":"crossref","unstructured":"Ferreri AJM, Teresa C, Marco CG, et al. (2019) R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-\u03b1 in primary CNS lymphoma. Blood 134(3)","DOI":"10.1182\/blood.2019000633"},{"issue":"1","key":"5301_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ejh.12980","volume":"100","author":"S Eloranta","year":"2018","unstructured":"Eloranta S, Br\u00e5nvall E, Celsing F et al (2018) Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000\u20132013. Eur J Haematol 100(1):61\u201368","journal-title":"Eur J Haematol"},{"key":"5301_CR5","doi-asserted-by":"crossref","unstructured":"Farrall AL, Smith JR (2021) Changing incidence and survival of primary central nervous system lymphoma in Australia: a 33-year national population-based study. Cancers (Basel) 13(3)","DOI":"10.3390\/cancers13030403"},{"issue":"12","key":"5301_CR6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/neuonc\/nos159","volume":"14","author":"M Weller","year":"2012","unstructured":"Weller M, Martus P, Roth P, Thiel E, Korfel A (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 14(12):1481\u20131484","journal-title":"Neuro Oncol"},{"key":"5301_CR7","doi-asserted-by":"crossref","unstructured":"Krebs S, Barasch JG, Young RJ, Grommes C, Sch\u00f6der H (2021) Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review. Ann Lymphoma. 5","DOI":"10.21037\/aol-20-52"},{"issue":"6","key":"5301_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00401-015-1399-y","volume":"129","author":"MG Best","year":"2015","unstructured":"Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T (2015) Liquid biopsies in patients with diffuse glioma. Acta Neuropathol 129(6):849\u2013865","journal-title":"Acta Neuropathol"},{"issue":"5","key":"5301_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","volume":"16","author":"M Roschewski","year":"2015","unstructured":"Roschewski M, Dunleavy K, Pittaluga S et al (2015) Circulating tumor DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16(5):541\u2013549","journal-title":"Lancet Oncol"},{"issue":"6","key":"5301_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1600-0609.2010.01516.x","volume":"85","author":"R Schroers","year":"2010","unstructured":"Schroers R, Baraniskin A, Heute C et al (2010) Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol 85(6):520\u2013528","journal-title":"Eur J Haematol"},{"issue":"11","key":"5301_CR11","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1182\/blood-2010-09-308684","volume":"117","author":"A Baraniskin","year":"2011","unstructured":"Baraniskin A, Kuhnhenn J, Schlegel U et al (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117(11):3140\u20133146","journal-title":"Blood"},{"issue":"28","key":"5301_CR12","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM, Young KH, Visco C et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3460\u20133467","journal-title":"J Clin Oncol"},{"issue":"8","key":"5301_CR13","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","volume":"112","author":"KH Young","year":"2008","unstructured":"Young KH, Leroy K, M\u00f8ller MB et al (2008) Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 112(8):3088\u20133098","journal-title":"Blood"},{"issue":"1","key":"5301_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00277-019-03821-9","volume":"99","author":"XG Yuan","year":"2020","unstructured":"Yuan XG, Huang YR, Yu T et al (2020) Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases. Ann Hematol 99(1):93\u2013104","journal-title":"Ann Hematol"},{"key":"5301_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.25259\/SNI_314_2020","volume":"11","author":"BD Radotra","year":"2020","unstructured":"Radotra BD, Parkhi M, Chatterjee D et al (2020) Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: experience from a tertiary Center in North India. Surg Neurol Int 11:424","journal-title":"Surg Neurol Int"},{"issue":"4","key":"5301_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s12185-014-1540-z","volume":"99","author":"S Dalia","year":"2014","unstructured":"Dalia S, Forsyth P, Chavez J et al (2014) Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol 99(4):450\u2013456","journal-title":"Int J Hematol"},{"issue":"2","key":"5301_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3171\/jns.2000.92.2.0261","volume":"92","author":"B Bataille","year":"2000","unstructured":"Bataille B, Delwail V, Menet E et al (2000) Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92(2):261\u2013266","journal-title":"J Neurosurg"},{"issue":"3","key":"5301_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.4103\/ajns.AJNS_208_20","volume":"15","author":"T Sopittapan","year":"2020","unstructured":"Sopittapan T, Tunthanathip T, Kaewborisutsakul A (2020) Outcome and prognostic factors of primary central nervous system lymphoma in Southern Thailand. Asian J Neurosurg 15(3):560\u2013565","journal-title":"Asian J Neurosurg"},{"issue":"4","key":"5301_CR19","doi-asserted-by":"publisher","first-page":"e02061","DOI":"10.1002\/brb3.2061","volume":"11","author":"D Gomes Candido Reis","year":"2021","unstructured":"Gomes Candido Reis D, Levy D, Lage L et al (2021) New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL). Brain Behav 11(4):e02061","journal-title":"Brain Behav"},{"issue":"1","key":"5301_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13000-019-0833-1","volume":"14","author":"P Niparuck","year":"2019","unstructured":"Niparuck P, Boonsakan P, Sutthippingkiat T et al (2019) Treatment outcome and prognostic factors in PCNSL. Diagn Pathol 14(1):56","journal-title":"Diagn Pathol"},{"key":"5301_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40478-016-0307-6","volume":"4","author":"HD Munch-Petersen","year":"2016","unstructured":"Munch-Petersen HD, Asmar F, Dimopoulos K et al (2016) TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathol Commun 4:40","journal-title":"Acta Neuropathol Commun"},{"issue":"23","key":"5301_CR22","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1182\/bloodadvances.2019000989","volume":"3","author":"D Villa","year":"2019","unstructured":"Villa D, Tan KL, Steidl C et al (2019) Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Adv 3(23):3953\u20133961","journal-title":"Blood Adv"},{"issue":"9","key":"5301_CR23","doi-asserted-by":"publisher","first-page":"e1626653","DOI":"10.1080\/2162402X.2019.1626653","volume":"8","author":"S Kim","year":"2019","unstructured":"Kim S, Nam SJ, Park C et al (2019) High tumoral PD-L1 expression and low PD-1(+) or CD8(+) tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. Oncoimmunology 8(9):e1626653","journal-title":"Oncoimmunology"},{"issue":"3","key":"5301_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","volume":"3","author":"N Nayyar","year":"2019","unstructured":"Nayyar N, White MD, Gill CM et al (2019) MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv 3(3):375\u2013383","journal-title":"Blood Adv"},{"issue":"7","key":"5301_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MG, Stewart C et al (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127(7):869\u2013881","journal-title":"Blood"},{"issue":"1","key":"5301_CR26","first-page":"vdaa018","volume":"2","author":"A Ou","year":"2020","unstructured":"Ou A, Sumrall A, Phuphanich S et al (2020) Primary CNS lymphoma commonly expresses immune response biomarkers. Neurooncol Adv 2(1):vdaa018","journal-title":"Neurooncol Adv"},{"issue":"10","key":"5301_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S et al (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37(10):823\u2013833","journal-title":"J Clin Oncol"},{"issue":"8","key":"5301_CR28","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","volume":"3","author":"G Illerhaus","year":"2016","unstructured":"Illerhaus G, Kasenda B, Ihorst G et al (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 3(8):e388\u2013e397","journal-title":"Lancet Haematol"},{"issue":"9","key":"5301_CR29","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125(9):1403\u20131410","journal-title":"Blood"},{"issue":"7","key":"5301_CR30","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"A Ferreri","year":"2022","unstructured":"Ferreri A, Cwynarski K, Pulczynski E et al (2022) Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 36(7):1870\u20131878","journal-title":"Leukemia"},{"issue":"11","key":"5301_CR31","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11(11):1036\u20131047","journal-title":"Lancet Oncol"},{"issue":"5","key":"5301_CR32","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","volume":"133","author":"C Grommes","year":"2019","unstructured":"Grommes C, Tang SS, Wolfe J et al (2019) Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood 133(5):436\u2013445","journal-title":"Blood"},{"key":"5301_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","volume":"226","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Zhang X (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226:205\u2013218","journal-title":"Immunol Rev"},{"issue":"3","key":"5301_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/bjh.17357","volume":"193","author":"A Ferreri","year":"2021","unstructured":"Ferreri A, Calimeri T, Lopedote P et al (2021) MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol 193(3):497\u2013505","journal-title":"Br J Haematol"},{"issue":"1","key":"5301_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-014-1622-z","volume":"121","author":"Y Sasagawa","year":"2015","unstructured":"Sasagawa Y, Akai T, Tachibana O, Iizuka H (2015) Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. J Neurooncol 121(1):177\u2013183","journal-title":"J Neurooncol"},{"key":"5301_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.03.080","volume":"61","author":"L Nguyen-Them","year":"2016","unstructured":"Nguyen-Them L, Costopoulos M, Tanguy ML et al (2016) The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur J Cancer 61:69\u201376","journal-title":"Eur J Cancer"},{"key":"5301_CR37","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.2147\/CMAR.S255482","volume":"12","author":"J Shao","year":"2020","unstructured":"Shao J, Chen K, Li Q et al (2020) High level of IL-10 in cerebrospinal fluid is specific for diagnosis of primary central nervous system lymphoma. Cancer Manag Res 12:6261\u20136268","journal-title":"Cancer Manag Res"},{"issue":"1","key":"5301_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12885-020-07774-5","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zou D, Yin J et al (2021) Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma. BMC Cancer 21(1):183","journal-title":"BMC Cancer"},{"issue":"4","key":"5301_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1053\/j.seminhematol.2017.06.005","volume":"55","author":"M Costopoulos","year":"2018","unstructured":"Costopoulos M, Kim R, Choquet S et al (2018) Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. Semin Hematol 55(4):179\u2013181","journal-title":"Semin Hematol"},{"issue":"8","key":"5301_CR40","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1007\/s00415-021-10453-5","volume":"268","author":"A Ungureanu","year":"2021","unstructured":"Ungureanu A, Le Garff-Tavernier M, Costopoulos M et al (2021) CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma. J Neurol 268(8):2890\u20132894","journal-title":"J Neurol"},{"issue":"3","key":"5301_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1600-0609.2010.01475.x","volume":"85","author":"R Schroers","year":"2010","unstructured":"Schroers R, Baraniskin A, Heute C et al (2010) Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol 85(3):236\u2013242","journal-title":"Eur J Haematol"},{"issue":"23","key":"5301_CR42","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1182\/blood-2013-01-476333","volume":"121","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Wong VS, Kadoch C et al (2013) CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 121(23):4740\u20134748","journal-title":"Blood"},{"key":"5301_CR43","doi-asserted-by":"publisher","first-page":"8725","DOI":"10.1038\/ncomms9725","volume":"6","author":"M Mihailovich","year":"2015","unstructured":"Mihailovich M, Bremang M, Spadotto V et al (2015) miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat Commun 6:8725","journal-title":"Nat Commun"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05301-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05301-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05301-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:06:32Z","timestamp":1689231992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05301-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5301"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05301-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"1 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved according to the ethical guidelines of the First Affiliated Hospital of Chongqing Medical University (institutional review board) and was performed according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}